1US FDA. FDA approves first drug to treat multi-drug resistant pulmonary tuberculosis[ EB/OL]. [2012 - 12 - 28 ]. http:// www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/ ucm333695, htm.
2JEROME E G, van GESTEL J F E, VENET M G, et al. Quin- oline derivatives and their use as mycobacterial inhibitors: WO,2004011436 [ P ]2004 - 02 - 05.
3OM IOKA H. Current status of some antituberculosis drugs ld the development of new antituberculous agents with spe- al reference to their in vitro and in vivo antimicrobial activi- s [ J ]. Curr Pharm Des,2006,12 ( 31 ) : 4047 - 4070.
4LOUNIS N,VEZIRIS N,CHAUFFOUR A, et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuber- culosis have the potential to shorten treatment duration E J ]. An- timicrob Agents Chemother,2006,50 (11 ) : 3543 -3547.
5VEZIRIS N, IBRAHIM M, LOUNIS N, et al. Once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis [ J ]. Am J Respir Crit Care Med,2009,179( 1 ) :75 -79.
6ANDRIES K,VERHASSELT P,GUILLEMONT J ,et al. A di- arylquinoline drug active on the ATP synthase of Mycobacteri- um tuberculosis [J ]. Science,2005,307 ( 5707 ) : 223 - 227.
7US FDA. FDA approves bedaquiline for the treatment of pa- tients with MDR-TB [ EB/OL ]. [2012 - 12 - 28 ]. http:// www. accessdata, fda. gov/drugsatfda docs/label/2012/ 204384s0001bl. pdf.
